Perivascular spaces, plasma GFAP, and speeded executive function in neurodegenerative diseases.
cerebrovascular diseases
executive function
neurodegenerative diseases
perivascular spaces
plasma glial fibrillary acidic protein
white matter hyperintensities
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
04 Jul 2024
04 Jul 2024
Historique:
revised:
29
05
2024
received:
14
03
2024
accepted:
29
05
2024
medline:
4
7
2024
pubmed:
4
7
2024
entrez:
4
7
2024
Statut:
aheadofprint
Résumé
We investigated the effect of perivascular spaces (PVS) volume on speeded executive function (sEF), as mediated by white matter hyperintensities (WMH) volume and plasma glial fibrillary acidic protein (GFAP) in neurodegenerative diseases. A mediation analysis was performed to assess the relationship between neuroimaging markers and plasma biomarkers on sEF in 333 participants clinically diagnosed with Alzheimer's disease/mild cognitive impairment, frontotemporal dementia, or cerebrovascular disease from the Ontario Neurodegenerative Disease Research Initiative. PVS was significantly associated with sEF (c = -0.125 ± 0.054, 95% bootstrap confidence interval [CI] [-0.2309, -0.0189], p = 0.021). This effect was mediated by both GFAP and WMH. In this unique clinical cohort of neurodegenerative diseases, we demonstrated that the effect of PVS on sEF was mediated by the presence of elevated plasma GFAP and white matter disease. These findings highlight the potential utility of imaging and plasma biomarkers in the current landscape of therapeutics targeting dementia. Perivascular spaces (PVS) and white matter hyperintensities (WMH) are imaging markers of small vessel disease. Plasma glial fibrillary protein acidic protein (GFAP) is a biomarker of astroglial injury. PVS, WMH, and GFAP are relevant in executive dysfunction from neurodegeneration. PVS's effect on executive function was mediated by GFAP and white matter disease.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Alzheimer Society of London
Organisme : Middlesex Doctoral Graduate Research Scholarship
Organisme : Dr. Sandra Black Centre for Brain Resilience and Recovery
Organisme : Linda C. Campbell Foundation
Organisme : Weston UK Brain Institute,
Organisme : Foundation Leducq Transatlantic Network of Excellence for their support of PVS-related studies
Organisme : Swedish Research Council
ID : #2023-00356
Organisme : Swedish Research Council
ID : #2022-01018
Organisme : Swedish Research Council
ID : #2019-02397
Organisme : European Union's Horizon Europe research and innovation programme
ID : 101053962
Organisme : Swedish State Support for Clinical Research
ID : #ALFGBG-71320
Organisme : Alzheimer Drug Discovery Foundation (ADDF)
ID : #201809-2016862
Organisme : AD Strategic Fund
Organisme : Alzheimer's Association
ID : #ADSF-21-831376-C
Pays : United States
Organisme : Alzheimer's Association
ID : #ADSF-21-831381-C
Pays : United States
Organisme : Alzheimer's Association
ID : #ADSF-21-831377-C
Pays : United States
Organisme : Bluefield Project, Cure Alzheimer's Fund
Organisme : Olav Thon Foundation
Organisme : Erling-Persson Family Foundation
Organisme : Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden
ID : #FO2022-0270
Organisme : European Union's Horizon 2020 research and innovation programme
Organisme : European Union Joint Programme-Neurodegenerative Disease Research
ID : JPND2021-00694
Organisme : National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre
Organisme : UK Dementia Research Institute at UCL
ID : UKDRI-1003
Organisme : Brain and Behavior Foundation
Organisme : National Institute on Ageing
Organisme : BrightFocus Foundation
Organisme : Canadian Institute of Health Research
Organisme : Canadian Consortium on Neurodegeneration in Aging
Organisme : Centre for Ageing and Brain Health Innovation
Organisme : Centre for Addiction and Mental Health
Informations de copyright
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Bakker ENTP, Bacskai BJ, Arbel‐Ornath M, et al. Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases. Cell Mol Neurobiol. 2016;36:181‐194. doi:10.1007/s10571‐015‐0273‐8
Shulyatnikova T, Hayden MR. Why are perivascular spaces important? Medicina. 2023;59:917. doi:10.3390/medicina59050917
Jessen NA, Munk ASF, Lundgaard I, Nedergaard M. The glymphatic system: a beginner's guide. Neurochem Res. 2015;40:2583‐2599. doi:10.1007/s11064‐015‐1581‐6
Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurology. 2018;17:1016‐1024. doi:10.1016/S1474‐4422(18)30318‐1
Charidimou A, Hong YT, Jäger HR, et al. White matter perivascular spaces on magnetic resonance imaging: marker of cerebrovascular amyloid burden? Stroke. 2015;46:1707‐1709. doi:10.1161/STROKEAHA.115.009090
Ding J, Sigurðsson S, Jónsson PV, et al. Large Perivascular spaces visible on magnetic resonance imaging, cerebral small vessel disease progression, and risk of dementia: the age, gene/environment susceptibility–Reykjavik Study. JAMA Neurol. 2017;74:1105‐1112. doi:10.1001/jamaneurol.2017.1397
Kress BT, Iliff JJ, Xia M, et al. Impairment of paravascular clearance pathways in the aging brain. Ann Neurol. 2014;76:845‐861. doi:10.1002/ana.24271
Ramirez J, Berezuk C, McNeely AA, Scott CJM, Gao F, Black SE. Visible Virchow‐Robin spaces on magnetic resonance imaging of Alzheimer's disease patients and normal elderly from the Sunnybrook Dementia Study. J Alzheimers Dis. 2015;43:415‐424. doi:10.3233/JAD‐132528
Ramirez J, Berezuk C, McNeely AA, Gao F, McLaurin J, Black SE. Imaging the perivascular space as a potential biomarker of neurovascular and neurodegenerative diseases. Cell Mol Neurobiol. 2016;36:289‐299. doi:10.1007/s10571‐016‐0343‐6
Smeijer D, Ikram MK, Hilal S. Enlarged perivascular spaces and dementia: a systematic review. J Alzheimers Dis. 2019;72:247‐256. doi:10.3233/JAD‐190527
Tarasoff‐Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain—implications for Alzheimer disease. Nat Rev Neurol. 2015;11:457‐470. doi:10.1038/nrneurol.2015.119
Wardlaw JM, Benveniste H, Nedergaard M, et al. Perivascular spaces in the brain: anatomy, physiology and pathology. Nat Rev Neurol. 2020;16:137‐153. doi:10.1038/s41582‐020‐0312‐z
Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12:822‐838. doi:10.1016/S1474‐4422(13)70124‐8
Passiak BS, Liu D, Kresge HA, et al. Perivascular spaces contribute to cognition beyond other small vessel disease markers. Neurology. 2019;92:e1309‐e1321. doi:10.1212/WNL.0000000000007124
Jeong SH, Cha J, Park M, et al. Association of enlarged perivascular spaces with amyloid burden and cognitive decline in Alzheimer disease continuum. Neurology. 2022;99(16):e1791‐e1802. doi:10.1212/WNL.0000000000200989
Choe YM, Baek H, Choi HJ, et al. Association between enlarged perivascular spaces and cognition in a memory clinic population. Neurology. 2022;99(13):e1414‐e1421. doi:10.1212/WNL.0000000000200910
Hilal S, Tan CS, Adams HHH, et al. Enlarged perivascular spaces and cognition: a meta‐analysis of 5 population‐based studies. Neurology. 2018;91:e832‐e842. doi:10.1212/WNL.0000000000006079
Prins ND, van Dijk EJ, denHeijer T, et al. Cerebral small‐vessel disease and decline in information processing speed, executive function and memory. Brain. 2005;128:2034‐2041. doi:10.1093/brain/awh553
Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta‐analysis. BMJ. 2010;341:c3666. doi:10.1136/bmj.c3666
Ottoy J, Ozzoude M, Zukotynski K, et al. Vascular burden and cognition: mediating roles of neurodegeneration and amyloid PET. Alzheimers Dement. 2023;19:1503‐1517. doi:10.1002/alz.12750
Mestre H, Kostrikov S, Mehta RI, Nedergaard M. Perivascular spaces, glymphatic dysfunction, and small vessel disease. Clin Sci. 2017;131:2257‐2274. doi:10.1042/CS20160381
Yang Z, Wang KKW. Glial fibrillary acidic protein: from intermediate filament assembly and gliosis to neurobiomarker. Trends Neurosci. 2015;38:364‐374. doi:10.1016/j.tins.2015.04.003
Hase Y, Chen A, Bates LL, et al. Severe white matter astrocytopathy in CADASIL. Brain Pathol. 2018;28:832‐843. doi:10.1111/bpa.12621
Gouw AA, Seewann A, Vrenken H, et al. Heterogeneity of white matter hyperintensities in Alzheimer's disease: post‐mortem quantitative MRI and neuropathology. Brain. 2008;131:3286‐3298. doi:10.1093/brain/awn265
Ferreira PCL, Zhang Y, Snitz B, et al. Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real‐world population‐based cohort. Alzheimers Dement. 2023;19(10):4507‐4519. doi:10.1002/alz.12986
Benussi A, Ashton NJ, Karikari TK, et al. Serum Glial Fibrillary Acidic Protein (GFAP) is a marker of disease severity in frontotemporal lobar degeneration. J Alzheimers Dis. 2020;77:1129‐1141. doi:10.3233/JAD‐200608
Huss A, Abdelhak A, Mayer B, et al. Association of serum GFAP with functional and neurocognitive outcome in sporadic small vessel disease. Biomedicines. 2022;10:1869. doi:10.3390/biomedicines10081869
Shir D, Graff‐Radford J, Hofrenning EI, et al. Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology. Alzheimers Dement. 2022;14:e12291. doi:10.1002/dad2.12291
Asken BM, VandeVrede L, Rojas JC, et al. Lower white matter volume and worse executive functioning reflected in higher levels of plasma GFAP among older adults with and without cognitive impairment. J Int Neuropsychol Soc. 2022;28:588‐599. doi:10.1017/S1355617721000813
Verberk IMW, Laarhuis MB, van den Bosch KA, et al. Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic‐based cohort study. Lancet Healthy Longev. 2021;2:e87‐e95. doi:10.1016/S2666‐7568(20)30061‐1
Revised Criteria for Diagnosis and Staging of Alzheimer's. AAIC. n.d.. Accessed November 17, 2023. https://aaic.alz.org/diagnostic‐criteria.asp
Farhan SMK, Bartha R, Black SE, et al. The Ontario Neurodegenerative Disease Research Initiative (ONDRI). Can J Neurol Sci. 2017;44:196‐202. doi:10.1017/cjn.2016.415
Sunderland KM, Beaton D, Arnott SR, et al. Characteristics of the Ontario Neurodegenerative Disease Research initiative cohort. Alzheimers Dement. 2023;19:226‐243. doi:10.1002/alz.12632
Ramirez J, Holmes MF, Scott CJM, et al. Ontario Neurodegenerative Disease Research Initiative (ONDRI): structural MRI methods and outcome measures. Front Neurol. 2020;11:847. doi:10.3389/fneur.2020.00847
Kovacevic N, Lobaugh NJ, Bronskill MJ, Levine B, Feinstein A, Black SE. A robust method for extraction and automatic segmentation of brain images. Neuroimage. 2002;17:1087‐1100. doi:10.1006/nimg.2002.1221
Ramirez J, Gibson E, Quddus A, et al. Lesion Explorer: a comprehensive segmentation and parcellation package to obtain regional volumetrics for subcortical hyperintensities and intracranial tissue. Neuroimage. 2011;54:963‐973. doi:10.1016/j.neuroimage.2010.09.013
Gibson E, Gao F, Black SE, Lobaugh NJ. Automatic segmentation of white matter hyperintensities in the elderly using FLAIR images at 3T. J Magn Reson Imaging. 2010;31:1311‐1322. doi:10.1002/jmri.22004
Sunderland KM, Beaton D, Fraser J, et al. The utility of multivariate outlier detection techniques for data quality evaluation in large studies: an application within the ONDRI project. BMC Med Res Methodol. 2019;19:102. doi:10.1186/s12874‐019‐0737‐5
McLaughlin PM, Sunderland KM, Beaton D, et al. The quality assurance and quality control protocol for neuropsychological data collection and curation in the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study. Assessment. 2021;28:1267‐1286. doi:10.1177/1073191120913933
Dilliott AA, Evans EC, Farhan SMK, et al. Genetic variation in the Ontario Neurodegenerative Disease Research Initiative. Can J Neurol Sci. 2019;46:491‐498. doi:10.1017/cjn.2019.228
Farhan SMK, Dilliott AA, Ghani M, et al. The ONDRISeq panel: custom‐designed next‐generation sequencing of genes related to neurodegeneration. NPJ Genom Med. 2016;1:16032. doi:10.1038/npjgenmed.2016.32
Lahna D, Roese N, Woltjer R, et al. Postmortem 7T MRI for guided histopathology and evaluation of cerebrovascular disease. J Neuropathol Exp Neurol. 2022;82:57‐70. doi:10.1093/jnen/nlac103
Keith J, Gao F‐Q, Noor R, et al. Collagenosis of the deep medullary veins: an underrecognized pathologic correlate of white matter hyperintensities and periventricular infarction? J Neuropathol Exp Neurol. 2017;76:299‐312. doi:10.1093/jnen/nlx009
Lahna D, Schwartz DL, Woltjer R, et al. Venous collagenosis as pathogenesis of white matter hyperintensity. Ann Neurol. 2022;92:992‐1000. doi:10.1002/ana.26487
Solé‐Guardia G, Custers E, de Lange A, et al. Association between hypertension and neurovascular inflammation in both normal‐appearing white matter and white matter hyperintensities. Acta Neuropathol Commun. 2023;11:2. doi:10.1186/s40478‐022‐01497‐3
Jagust WJ, Teunissen CE, DeCarli C. The complex pathway between amyloid β and cognition: implications for therapy. Lancet Neurol. 2023;22:847‐857. doi:10.1016/S1474‐4422(23)00128‐X
Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI‐neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21:714‐725. doi:10.1016/S1474‐4422(22)00208‐3
Hosoki S, Hansra GK, Jayasena T, et al. Molecular biomarkers for vascular cognitive impairment and dementia. Nat Rev Neurol. 2023;19:737‐753. doi:10.1038/s41582‐023‐00884‐1
Montagne A, Nation DA, Sagare AP, et al. APOE4 leads to blood‐brain barrier dysfunction predicting cognitive decline. Nature. 2020;581:71‐76. doi:10.1038/s41586‐020‐2247‐3
Hinman JD, Elahi F, Chong D, et al. Placental growth factor as a sensitive biomarker for vascular cognitive impairment. Alzheimers Dement. 2023;19:3519‐3527. doi:10.1002/alz.12974